From: Therapy for metastatic melanoma: the past, present, and future
Trial | Patients | RR% (CR/PR) | PFS (month) | OS | Number (patients) | Summary |
---|---|---|---|---|---|---|
Single Arm Phase 2 Kim KB et al. [52] | Imatinib mesylate 400 mg bid in advanced unresectable melanoma | 5% | 1.4 | 7.5 months | 21 | Imatinib mesylate demonstrated a response in 1 patient who also had high c-kit expression and alternate splicing variant in c-kit mRNA transcript. |
Single Arm Phase 2 Carvajal et al. [54] | Imatinib mesylate 400 mg bid in advanced unresectable melanoma | 16% | 3 | 46.3 weeks | 28 | Imatinib mesylate demonstrated a significant clinical response in subset of patients with cKit mutation and advanced melanomaa |
Single Arm Phase 2 Guo et al. [53] | Imatinib mesylate 400 mg daily in metastatic melanoma | 23.3% | 3.5 | 14 months | 43 | Imatinib mesylate demonstrated a significant clinical response in a subset of patients with cKit mutation and metastatic melanomaa |